Skip to content

Study · Non-randomized trial · n = 15 · 1990

3 results

The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.

Whitehouse RW, Adams JE, Bancroft K, Vaughan-Williams CA, Elstein M

Clinical endocrinology1 Sept 1990Cited by 44 (Europe PMC)

PMID2147597 (opens in a new tab)DOI10.1111/j.1365-2265.1990.tb00501.x (opens in a new tab)PepBankPUB-02147597
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women with endometriosis, nafarelin reduced spinal trabecular bone mineral by 9.6 g/l (5.9%) after 6 months.

    In plain wordsIn women with endometriosis, spinal bone mineral decreased after 6 months of nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseSpinal trabecular bone mineral loss
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Bone mineral change
    −9.6 g/l
    nafarelin
    Bone mineral change
    −5.9%
    nafarelin
    P value
    < 0.001
    change

    Source sentences

    Summary
    Significant loss of bone mineral (-9.6 g/l; -5.9% P less than 0.001) was demonstrated after 6 months' treatment with nafarelin.
    1 context sentence
    Summary · context
    Single and dual-energy quantitative computed tomography (QCT) were used to measure spinal trabecular bone mineral content in 24 women treated with either nafarelin (15 patients) or danazol (nine patients) for endometriosis.
  2. 02HumanNon-randomized trialSafety outcome

    In women with endometriosis, the bone mineral loss seen with nafarelin was reversible, with no significant difference from pre-treatment at 6 months after treatment was stopped (difference -1.95 g/l, NS).

    In plain wordsIn women with endometriosis, the bone loss seen with nafarelin was reversible and did not differ significantly from baseline 6 months after stopping.

    Peptide
    Nafarelin
    Outcome
    No significant changeBone mineral after withdrawal
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Bone mineral difference
    −1.95 g/l
    6 months after withdrawal

    Source sentences

    Summary
    This loss was reversible with no significant difference in the bone mineral measurement made before treatment and that made at 6 months after treatment was stopped (difference -1.95 g/l, NS).
    1 context sentence
    Summary · context
    Single and dual-energy quantitative computed tomography (QCT) were used to measure spinal trabecular bone mineral content in 24 women treated with either nafarelin (15 patients) or danazol (nine patients) for endometriosis.
  3. 03HumanObservational studyMechanism

    In women receiving nafarelin, mean serum oestradiol correlated positively with bone mineral change (r = 0.655, P less than 0.005).

    In plain wordsIn women receiving nafarelin, higher oestradiol was linked to higher bone mineral change.

    Peptide
    Nafarelin
    Outcome
    IncreaseOestradiol and bone mineral change correlation
    Study

    n = 15

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Correlation coefficient
    0.655
    oestradiol and bone mineral change
    P value
    < 0.005
    correlation

    Source sentences

    Summary
    A significant correlation was demonstrated between mean serum oestradiol levels during treatment with nafarelin and the change in bone mineral (r = 0.655, P less than 0.005).
    1 context sentence
    Summary · context
    Single and dual-energy quantitative computed tomography (QCT) were used to measure spinal trabecular bone mineral content in 24 women treated with either nafarelin (15 patients) or danazol (nine patients) for endometriosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.